Annexin announces allowance of a new U.S. Patent covering manufacturing of ANXV
Annexin Pharmaceuticals AB (publ) announces that the U.S. Patent and Trademark Office has allowed an issue of the new patent, further strengthening the intellectual property and key coverage for the Annexin ‘s therapeutic product candidate ANXV.STOCKHOLM (22 April, 2022) - ANXV is a human Annexin A5 produced by recombinant technology in a living bacterial system. Production processes of biologic drug candidates such as ANXV are highly complex. A considerable amount of time, knowledge, efforts and investments are required to produce such proteins at a quality and quantity that are